Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of the SARS-CoV-2 P.1 and B.1.351 variants, which are not susceptible to the combination therapy, the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced today.

ASPR also continues to suspend distribution of bamlanivimab and etesevimab in Arizona, California, Florida, Illinois, Indiana, Massachusetts, Oregon and Washington due to spread of one or both of these variants in those states.

The Food and Drug Administration recommends providers in R.I. and these other states use the alternative monoclonal antibody therapies REGEN-COV or sotrovimab, which are likely to remain active against these variants, ASPR said. The announcement does not affect other states, but providers should monitor the frequency of the P.1 and B.1.351 variants in their region and review the fact sheets for each authorized monoclonal antibody therapy for details regarding specific variants and resistance, ASPR said.

Related News Articles

Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…
Headline
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-…